Induction of innate immunity by nasal influenza vaccine administered in combination with an adjuvant (cholera toxin)

Vaccine

Volumn 18, Issue 24, 2000, Pages 2713-2722

  Matsuo, Kazutoshi ^a   Yoshikawa, Tomoki ^a   Asanuma, Hideki ^a   Iwasaki, Takuya ^a   Hagiwara, Yukari ^a   Chen, Ze ^a   Kadowaki, Shin Etsu ^a   Tsujimoto, Hajime ^b   Kurata, Takeshi ^a   Tamura, Shin Ichi ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Cholera toxin; Innate immunity; Nasal influenza vaccine

Indexed keywords

ADJUVANT; CHOLERA TOXIN; CHOLERA TOXIN B SUBUNIT; CYTOKINE; IMMUNOGLOBULIN A ANTIBODY; INFLUENZA VACCINE; INTERLEUKIN 1BETA; MESSENGER RNA; VIRUS ANTIGEN;

ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIGEN PRESENTING CELL; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNITY; IMMUNIZATION; INFLUENZA VIRUS; INFLUENZA VIRUS A; MOUSE; NATURAL KILLER CELL; NONHUMAN; NOSE MUCUS; PRIORITY JOURNAL; VIRUS PLAQUE;

EID: 0034213483     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00055-4     Document Type: Article

References (41)

1. Couch R.B., Kasel J.A. Immunity to influenza in man. Annu. Rev. Microbiol. 37:1989;529-549.
2. Liew F.Y., Russel S.M., Appleyard G., Brand C.M., Beale J. Cross-protection in mice infected with influenza A virus by the respiratory route is correlated with local IgA antibody rather than serum antibody or cytotoxic T cell activity. Eur. J. Immunol. 14:1984;351-356.
3. Waldman R.H., Wigley F.M., Small P.A. Jr. Specificity of respiratory secretion antibody against influenza virus. J. Immunol. 105:1970;1477-1483.
4. Tamura S.-I., Asanuma H., Ito Y., Hirabayashi Y., Suzuki Y., Nagamine T., Aizawa C., Kurata T., Oya A. Superior cross-protective effect of nasal vaccination to subcutaneous inoculation with influenza HA vaccine. Eur. J. Immunol. 22:1992;477-481.
5. Tamura S.-I., Ito Y., Asanuma H., Hirabayashi Y., Suzuki Y., Nagamine T., Aizawa C., Kurata T. Cross-protection against influenza virus infection afforded by trivalent inactivated vaccines inoculated intranasally with cholera toxin B subunit. J. Immunol. 149:1992;981-988.
6. Tamura S.-I., Yamanaka A., Shimohara M., Tomita T., Komase K., Tsuda Y., Suzuki Y., Nagamine T., Kawahara K., Danbara H., Aizawa C., Oya A., Kurata T. Synergistic action of cholera toxin B subunit (and E. coli heat-labile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenza vaccine. Vaccine. 12:1994;419-426.
7. Chen K.-S., Strober W. Cholera holotoxin and its B subunit enhance Peyer's patch B cell responses induced by orally administered influenza virus: disproportionate cholera toxin enhancement of the IgA B cell response. Eur. J. Immunol. 20:1990;433-436.
8. Hornquist E., Lycke N. Cholera toxin adjuvant greatly promotes antigen priming of T cells. Eur. J. Immunol. 23:1993;2136-2143.
9. Cong Y., Weaver C.T., Elson C.O. The mucosal adjuvanticity of cholera toxin involves enhancement of costimulatory activity by selective up-regulation of B7.2 expression. J. Immunol. 159:1997;5301-5308.
10. Bromander A.K., Kjerrulf M., Holmgren J., Lycke N. Cholera toxin enhances alloantigen presentation by cultured intestinal epithelial cells. Scand. J. Immunol. 37:1993;452-458.
11. McGee D.W., Elson C.O., McGhee J.R. Enhancing effect of cholera toxin on interleukin-6 secretion by IEC-6 intestinal epithelial cells: mode of action and augmenting effect of inflammatory cytokines. Infect. Immun. 61:1993;4637-4644.
12. Bromander A., Holmgren J., Lycke N. Cholera toxin stimulates IL-1 production and enhances antigen presentation by macrophages in vitro. J. Immunol. 146:1991;2908-2914.
13. Hirabayashi Y., Tamura S.-I., Shimada K., Kurata T. Involvement of antigen-presenting cells in the enhancement of the in vitro antibody responses to influenza virus haemagglutinin. Immunology. 75:1992;493-498.
14. Hoffmann J.A., Kafatos F.C., Janeway C.A., Ezekowitz R.A.B. Phylogenetic perspectives in innate immunity. Science. 284:1999;1313-1318.
15. Koornstra P.J., De Jong F.I.C.R.S., Vlek L.M.K., Marres E.H.M.A., Van Breda Vriesman P.J.C. The waldeyer ring equivalent in the rat. Acta Otolaryngol (Stockh.). 111:1991;591-599.
16. Kuper C.F., Koornstra P.J., Hameleers D.M.H., Biewenga J., Spit B.J., Duijvestijn A.M., Van Breda Vriesman P.J.C., Sminia T. The role of nasopharyngeal lymphoid tissue. Immunol. Today. 13:1992;219-224.
17. Asanuma H., Inaba Y., Aizawa C., Kurata T., Tamura S.-I. Characterization of mouse nasal lymphocytes isolated by enzymatic extraction with collagenase. J. Immunol. Methods. 187:1995;41-51.
18. Asanuma H., Thompson A.H., Iwasaki T., Sato Y., Inaba Y., Aizawa C., Kurata T., Tamura S.-I. Isolation and characterization of mouse nasal-associated lymphoid tissue. J. Immunol. Methods. 202:1997;123-131.
19. Asanuma H., Aizawa C., Kurata T., Tamura S.-I. IgA antibody-forming cell responses in the nasal-associated lymphoid tissue of mice vaccinated by intranasal, intravenous and/or subcutaneous administration. Vaccine. 16:1998;1257-1262.
20. Tamura S.-I., Iwasaki T., Thompson A.H., Asanuma H., Chen Z., Suzuki Y., Aizawa C., Kurata T. Antibody-forming cells in the nasal-associated lymphoid tissue during primary influenza virus infection. J. Gen. Virol. 79:1998;291-299.
21. Tobita K., Sugiura A., Enomoto C., Furuyama M. Plaque assay and primary isolation of influenza A viruses in an established line of canine kidney cells (MDCK) in the presence of trypsin. Med. Microbiol. Immunol. 162:1975;9-14.
22. Matsuo K, Iwasaki T, Asanuma H, Yoshikawa T, Chen Z, Tsujimoto H, Kurata T, Tamura S-I. Cytokine mRNAs in the nasal-associated lymphoid tissue during influenza virus infection and nasal vaccination, Vaccine 2000;18:1344-50.
23. Schoenhaut D.S., Chua A.O., Wolitzky A.G., Quinn P.M., Dwyer C.M., Gately M.K., Gubler U. Cloning and expression of murine IL-12. J. Immunol. 148:1992;3433-3440.
24. Anderson D.M., Johnson L., Glaccum M.B., Copeland N.G., Gilbert D.J., Jenkins N.A., Valentine V., Kirstein M.N., Shapiro D.N., Morris S., Grabstein K., Cosman D. Chromosomal assignment and genomic structure of IL-15. Genomics. 25:1995;701-706.
25. Tone M., Thompson S.A.J., Tone Y., Fairchild P.J., Waldman H. Regulation of interleukin-18 (interferon-gamma-inducing factor) gene expression. J. Immunol. 159:1997;6156-6163.
26. Alonso S., Minty A., Bourlet Y., Buckingham M.E. Comparison of three actin-coding sequences in the mouse: evolutionary relationships between the actin genes of warm-blooded vertebrates. J. Mol. Evol. 23:1986;11-22.
27. + T cells in the absence of TCR ligation. J. Immunol. 161:1998;3408-3415.
28. Fawaz L.M., Sharif-Askari E., Menezes J. Up-regulation of NK cytotoxic activity via IL-15 induction by different viruses: a comparative study. J. Immunol. 163:1999;4473-4480.
29. Dinarello C.A. Interleukin-18. Methods. 19:1999;121-132.
30. Lauwerys B.R., Renauld J.C., Houssiau F.A. Synergistic proliferation and activation of natural killer cells by interleukin 12 and interleukin 18. Cytokine. 11:1999;822-830.
31. Monteiro J.M., Harvey C., Trichieri G. Role of interleukin-12 in primary influenza virus infection. J. Virol. 72:1998;4825-4831.
32. Biron C.A., Nguyen K.B., Pien G.C., Cousens L.P., Salazar-Mather T.P. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu. Rev. Immunol. 17:1999;189-220.
33. Wewers M.D., Dare H.A., Winnard A.V., Parker J.M., Miller D.K. IL-1 beta-converting enzyme (ICE) is present and functional in human alveplar macrophages: macrophage IL-1 beta release limitation is ICE independent. J. Immunol. 159:1997;5964-5972.
34. Zepter K., Haffner A., Soohoo L.F., De Luca D., Tang H.P., Fisher P., Chavinson J., Elmets C.A. Induction of biologically active IL-1 beta-converting enzyme and mature IL-1 beta in human keratinocytes by inflammatory and immunologic stimuli. J. Immunol. 159:1997;6203-6208.
35. Rappuoli R., Pizza M., Douce G., Dougan G. Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins. Immunol. Today. 20:1999;493-500.
36. Dinarello C.A. Biologic basis for interleukin-1 in disease. Blood. 87:1996;2095-2147.
37. Gizurarson S., Tamura S.-I., Aizawa C., Kurata T. Stimulation of the transepithelial flux of influenza HA vaccine by cholera toxin B subunit. Vaccine. 10:1992;101-106.
38. Lycke N., Karisson U., Sjolander A., Magnisson K.E. The adjuvant action of cholera toxin is associated with an increased intestinal permeability for luminal antigens. Scand. J. Immunol. 33:1991;691-698.
39. Tamura S.-I., Ishihara K., Miyata K., Aizawa C., Kurata T. Mechanism of enhancement of the immune responses to influenza vaccine with cholera toxin B subunit and a trace amount of holotoxin. Vaccine. 13:1995;339-341.
40. Bluestone J.A. New perspective of CD28-B7-mediated T cell costimulation. Immunity. 2:1995;555-559.
41. Freeman G.J., Boussiotis V.A., Anumanthan A., Bernstein G.M., Ke X.Y., Rennert P.D., Gray G.S., Gribben J.G., Nadler L.M. B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4. Immunity. 2:1995;523-532.